Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

DexCom, Inc. - Common Stock (NQ:DXCM)

72.60 +0.33 (+0.46%)
Streaming Delayed Price Updated: 1:22 PM EST, Feb 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about DexCom, Inc. - Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
News headline image
Dexcom to Host Investor Day on June 23, 2023
From DexCom, Inc.
Via Business Wire
News headline image
Dexcom Announces Upcoming Conference Presentation
From DexCom, Inc.
Via Business Wire
News headline image
Dexcom Prices Upsized Offering of $1.1 Billion of 0.375% Convertible Senior Notes Due 2028
From DexCom, Inc.
Via Business Wire
News headline image
Dexcom Announces Proposed Offering of $1.0 Billion of Convertible Senior Notes
From DexCom, Inc.
Via Business Wire
News headline image
Dexcom Reports First Quarter 2023 Financial Results
From DexCom, Inc.
Via Business Wire
News headline image
Dexcom G6 Real-Time CGM System Now Accessible to Any Eligible Client Managing Diabetes With Insulin Through NIHB
From Dexcom, Inc.
Via Business Wire
News headline image
3 Medtech Companies with Higher Future Share Prices
The analysts see normalization and growth for the med tech industry and have started picking their favorites for 2023 and beyond. 
Via MarketBeat
News headline image
Diversified Abbott Laboratories Could Reverse And Move Higher
Abbott Laboratories reported a solid quarter driven by gains in the core business that are accelerating as COVID sales decline. 
Via MarketBeat
News headline image
Healthcare Innovation Drives Medical Device Makers To New Highs
Medical products makers Stryker and Boston Scientific are rallying to all-time highs, while sector peer DexCom is forming a constructive base. 
Via MarketBeat
News headline image
Dexcom Commends Decision to Expand CGM Medicare Coverage to Include People With Diabetes Using All Types of Insulin
From Dexcom, Inc.
Via Business Wire
News headline image
Dexcom Schedules First Quarter 2023 Earnings Release and Conference Call for April 27, 2023 at 4:30 p.m. Eastern Time
From DexCom, Inc.
Via Business Wire
News headline image
Dexcom Publishes Annual Sustainability Report
From DexCom, Inc.
Via Business Wire
News headline image
DexCom Comments on SVB Relationship
From DexCom, Inc.
Via Business Wire
News headline image
Dexcom Announces Upcoming Conference Presentations
From DexCom, Inc.
Via Business Wire
News headline image
Dexcom G7 Continuous Glucose Monitoring System Will Be Available to Medicare Beneficiaries at Launch
From Dexcom, Inc.
Via Business Wire
News headline image
Dexcom Reports Fourth Quarter and Fiscal Year 2022 Financial Results
From DexCom, Inc.
Via Business Wire
InvestorNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Expanding Platform to Integrate Market-Leading CGM Data
Via Investor Brand Network
News headline image
Dexcom and Nick Jonas Make Super Bowl Magic to Launch New Dexcom G7 Continuous Glucose Monitoring System
From DexCom, Inc.
Via Business Wire
News headline image
Dexcom Schedules Fourth Quarter and Full Year 2022 Earnings Release and Conference Call for February 9, 2023 at 4:30 p.m. Eastern Time
From DexCom, Inc.
Via Business Wire
News headline image
Insulet Has Potential To Gain More Than Analysts Are Forecasting
Even as it pulled back with the broader market Tuesday, insulin pump maker Insulet found support along its 50-day line and remained in possible buy range. 
Via MarketBeat
News headline image
Dexcom Reports Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2022 and Initial 2023 Outlook
From DexCom, Inc.
Via Business Wire
News headline image
Dexcom Appoints Teri Lawver as Chief Commercial Officer
From DexCom, Inc.
Via Business Wire
News headline image
Dexcom to Present at 41st Annual J.P. Morgan Healthcare Conference
From DexCom, Inc.
Via Business Wire
News headline image
Can FDA Approval Bolster DexCom, Inc.?
Dexcom is relying on the interest and sales of its new continuous glucose monitor--which recently received FDA approval--to boost revenue (and stock value). 
Via MarketBeat
Kaival Brands ($KAVL) and KMS gear up for anticipated revenue growth by hiring former Swisher International VP of Sales
Via AB Newswire
Topics Economy
News headline image
Dexcom G7 Receives FDA Clearance: The Most Accurate Continuous Glucose Monitoring System Cleared in the U.S.
From DexCom, Inc.
Via Business Wire
News headline image
Dexcom Announces Upcoming Conference Presentation
From DexCom, Inc.
Via Business Wire
News headline image
S&P 500 Component DexCom Set For Further Price, Earnings Growth
Glucose monitor maker DexCom surged 19% after its Q3 report, and shares are holding those gains. Wall Street sees more growth ahead in 2023. 
Via MarketBeat
Topics Stocks
CapitalGainsReport Sector Spotlight: Wearable Health (DXCM, WHSI, IRTC, BTCY)
Via AB Newswire
Topics Artificial Intelligence
News headline image
Dexcom Partners With Warriors and Nonprofits to Artfully Advocate for Access to Diabetes Care
From DexCom, Inc.
Via Business Wire
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.